Blood Journals Portfolio/LinkedIn
Sep 9, 2025, 23:00
Blood Podcast Alert: LSD1 Inhibitors in SCD, Ruxolitinib+Dex in HLH, Low VWF Insights
Blood Journals Portfolio shared on LinkedIn:
”September is Sickle Cell Disease Awareness Month and together we are working to conquer SCD!
In this episode, “Ruxolitinib plus dexamethasone in newly diagnosed adult hemophagocytic lymphohistiocytosis; lysine-specific demethylase-1 inhibitors in sickle cell disease; and clinical characteristics of patients with low von Willebrand factor” the methodology of three articles are discussed that feature sickle cell disease studies.
Key points are:
- Ruxolitinib plus Dexamethasone in Newly Diagnosed Adult Hemophagocytic Lymphohistiocytosis (HLH): A prospective study demonstrated that the combination of ruxolitinib and dexamethasone (Ru-D regimen) had a high response rate and led to favorable short-term survival outcomes in adult HLH patients. All patients responded to the treatment, and no significant adverse effects were observed.
- Lysine-Specific Demethylase-1 (LSD1) Inhibitors in Sickle Cell Disease: Novel, potent, and orally bioavailable LSD1 inhibitors have been shown to induce fetal hemoglobin synthesis in a sickle cell disease mouse model. These inhibitors effectively reduce reactive oxygen species and improve red blood cell lifespan, offering a promising new class of therapies for sickle cell disease and other beta-globinopathies.
- Clinical Characteristics of Patients with Low Von Willebrand Factor: Insights into the clinical phenotype and pathophysiological mechanisms underlying qualitative low von Willebrand factor (VWF) have been explored. Patients with plasma VWF levels between 30 to 50 IU/dL often present with mucocutaneous bleeding and may require tailored management strategies.
Listen to the full episode here.
What are your thoughts on these advancements in sickle cell disease research?”
Stay tuned for the podcast series in hematology with Hemostasis Today.
-
Dec 12, 2025, 14:478 Posts Not to Miss From the ASH 2025 – Marc Carrier
-
Dec 12, 2025, 10:17Alyssa George on Clinical and Economic Impact of a Eptacog Beta
-
Dec 12, 2025, 09:53Ivan Budnik Awarded AHA Postdoctoral Fellowship! Aiming to Improve DVT Long-term Outcomes
-
Dec 12, 2025, 09:34Giles Platford on Baby Big: Plasma-Derived Drug Against Infant Botulism
-
Dec 12, 2025, 09:22Matteo Foschi Presents The New Expert Guidance on Minor Ischemic Stroke
-
Dec 12, 2025, 07:00Umberto Pensato on Cancer and Stroke
-
Dec 12, 2025, 06:48Steve Tuplin on A New Era in Haemophilia A Care: Reflections from ASH25
-
Dec 12, 2025, 06:30Anirban Sen Gupta on Synthetic Platelets
-
Dec 12, 2025, 05:59Gaetan Duport: A New Legislation for Medicines in Europe